Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166636 | 0.92 | PTGER1 (0.61) | PTGER1NPC1RAB9ASMN1; SMN2PTGER3 | |
| SCHEMBL4164383 | 0.85 | MEN1 (0.49) | PTGER1NPC1SMN1; SMN2PTGER3KDM4E | |
| SCHEMBL4167685 | 0.84 | PTGER1 (0.55) | PTGER1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3203629 | 0.83 | PTGER1 (0.53) | PTGER1SMN1; SMN2CNR1GAA | |
| SCHEMBL4155358 | 0.83 | PTGER1 (0.52) | PTGER1NPC1RAB9ASMN1; SMN2PTGER3 | |
| SCHEMBL4165897 | 0.81 | PTGER1 (0.49) | PTGER1SMN1; SMN2PTGER3GAA | |
| SCHEMBL4159777 | 0.81 | PTGER1 (0.47) | PTGER1PTGER3GAA | |
| SCHEMBL4159115 | 0.80 | HTT (0.52) | PTGER1NPC1RAB9ASMN1; SMN2PTGER3 | |
| SCHEMBL4171291 | 0.80 | PTGER1 (0.46) | PTGER1PTGER3GAA | |
| SCHEMBL4157725 | 0.79 | PTGER1 (0.54) | PTGER1NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | claimed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885NPC1 2297/4885RAB9A 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.